Vaccine

Details Vaccine Vaccine

2007-10-23

2007-10-23

Parkin, Jeffrey S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S184100, C424S204100

Reexamination Certificate

active

10049192

ABSTRACT:
The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

REFERENCES:
patent: 4341763 (1982-07-01), Zygraich
patent: 4571385 (1986-02-01), Greenberg et al.
patent: 5626851 (1997-05-01), Clark et al.
New Drugs and Variations To Existing Drugs [online]. Thearpeutic Goods Administration. Department of Community Services and Health, Austrlia. Especially p. 6. [retrieved on Jun. 27, 2006]. Retrieved from the internet: <URL:www.tga.gov.au/docs/pdf/pmrvformg.pdf>.
Glass et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006 Jul. 22, vol. 368, No. 9532, pp. 323-332.
Vesikari et al. Safely and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004 vol. 22, pp. 2836-2842.
Ruiz-Palacios et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. The New England Journal of Medicine 2006, vol. 354, No. 1, pp. 11-22.
Glass et al. The promise of new rotavirus vaccines. The New England Journal of Medicine 2006, vol. 354, No. 1, pp. 75-77.
Midthum, et al., “Single Gene Substitution Rotavirus Reassortants Containing the Major Neutralization Protein (VP7) of Human Rotavirus Serotype 4”,Journal of Clinical Microbiology, 24(5): 822-826 (1986).
Garbag-Chenon, et al., “Reactogenicity and Immunogenicity of Rotavirus WC3 Vaccine in 5-12-Month Old Infants”,Res. Virol., 140: 207-217 (1989).
Bernstein, et al., “Safety and Immunogenicity of Live, Attenuated Human Rotavirus Vaccine 89-12”,Vaccine, 16(4): 381-387 (1998).
Midthun, et al., “Rotavirus Vaccines: An Overview”,Clinical Microbiology Reviews, 9(3): 423-434 (1996).
Padilla-Noriega, et al., “Human Rotavirus Outer Capsid Protein (VP4) Gene”,Database EMBL ‘Online’ ROHVP40CP, Jul. 4, 1994 (XP002158486).
Crawford, et al., “Human Rotavirus Glycoprotein VP7 mRNA”,Database EMBL ‘Online’ HRU88717, Mar. 9, 1997 (XP002158487).

Affiliated with

Also associated with

Rating

Vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3830919